Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.

@article{Raeber2012VeryLC,
  title={Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.},
  author={Lorenz Raeber and Michael Magro and Giulio G Stefanini and Bindu Kalesan and Ron Theodoor van Domburg and Yoshinobu Onuma and Peter M. Wenaweser and Joost Daemen and Bernhard Meier and Peter J{\"u}ni and Patrick Washington Serruys and Stephan Windecker},
  journal={Circulation},
  year={2012},
  volume={125 9},
  pages={1110-21}
}
BACKGROUND Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). METHODS AND RESULTS We assessed the risk of stent thrombosis in a cohort of 12 339 patients with unrestricted use of drug-eluting stents (3819 SES, 4308 PES, 4212 EES… CONTINUE READING